Join to View Full Profile
750 E Adams StSyracuse, NY 13210
Phone+1 315-464-8200
Fax+1 214-645-2615
Dr. Homsi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jade Homsi is an oncologist in Dallas, TX at the University of Texas Southwestern Medical Center. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 22 years. He specializes in oncology and melanoma.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2004 - 2007
Mercy Hospital (St Louis)Residency, Internal Medicine, 2001 - 2004
Damascus University Faculty of MedicineClass of 1995
Certifications & Licensure
FL State Medical License 2004 - 2026
NY State Medical License 2024 - 2026
TX State Medical License 2009 - 2025
AZ State Medical License 2011 - 2018
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Aug 17
Roles: Principal Investigator
Publications & Presentations
PubMed
- Eph receptors activate myeloid checkpoint receptor LILRB5 to support tumor development.Yubo He, Chengcheng Zhang, Lingxiao Tan, Mi Deng, Xiaoye Liu
Cancer Immunology Research. 2025-03-27 - CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma.Soo J Park, David M Ellison, Ryan Weight, Jade Homsi, Guilherme Rabinowits
Future Oncology. 2025-02-01 - 4 citationsLILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development.Ryan Huang, Xiaoye Liu, Jaehyup Kim, Hui Deng, Mi Deng
Cancer Immunology Research. 2024-03-04
Grant Support
- Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for CancerUT SOUTHWESTERN MEDICAL CENTER2019–2025
- Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for CancerUT SOUTHWESTERN MEDICAL CENTER2019–2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
